Source: iQoncept / Shutterstock
Taysha Gene Therapies (NASDAQ:TSHA) just announced its Q4 2023 results.
- Taysha Gene Therapies exceeded expectations, reporting earnings per share of 92 cents, well above the analyst forecast of -11 cents.
- The company posted revenue of $3.60 million, surpassing the projected $2.65 million by a remarkable 36%.
InvestorPlace Earnings employs TradeSmith data to automate coverage of quarterly earnings reports. The project delivers key insights such as earnings per share, revenue figures, and how a company measures up against analyst predictions. These reports offer readers the most up-to-date financial figures without delays. To flag any concerns or errors, reach out to us at [email protected].
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/tsha-stock-earnings-taysha-gene-therapies-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC
